أعرض في EDS

Adrenocorticotropic hormone methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial

التفاصيل البيبلوغرافية
العنوان: Adrenocorticotropic hormone methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial
المؤلفون: Rohit Bakshi, Mohit Neema, Shahamat Tauhid, Steven Cen, Robert C. Axtell, Lilyana Amezcua, Regina Berkovich, Lawrence Steinman
المصدر: Therapeutic Advances in Neurological Disorders, Vol 10 (2017)
بيانات النشر: SAGE Publishing, 2017.
سنة النشر: 2017
مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Disease, Adrenocorticotropic hormone, lcsh:RC346-429, Lesion, 03 medical and health sciences, 0302 clinical medicine, Interferon β, Internal medicine, medicine, lcsh:Neurology. Diseases of the nervous system, Pharmacology, Bone mineral, Expanded Disability Status Scale, business.industry, Multiple sclerosis, medicine.disease, Surgery, 030104 developmental biology, Neurology, Methylprednisolone, Neurology (clinical), medicine.symptom, business, 030217 neurology & neurosurgery, medicine.drug
الوصف: Background: The objective of this study was to evaluate monthly intramuscular adrenocorticotropic hormone (ACTH) gel versus intravenous methylprednisolone (IVMP) add-on therapy to interferon β for breakthrough disease in patients with relapsing forms of multiple sclerosis. Methods: This was a prospective, open-label, examiner-blinded, 15-month pilot study evaluating patients with Expanded Disability Status Scale (EDSS) score 3.0–6.5 and at least one clinical relapse or new T2 or gadolinium-enhanced lesion in the previous year. Twenty-three patients were randomized to ACTH ( n = 12) or IVMP ( n = 11) and completed the study. The primary outcome measure was the cumulative number of relapses. Secondary outcomes included EDSS, Mental Health Inventory (MHI), plasma cytokines, MS Functional Composite (MSFC), Quality-of-Life (MS-QOL) score, bone mineral density (BMD), and new or worsened psychiatric symptoms per month. Brain magnetic resonance imaging was analyzed post hoc. This was a preliminary and small-scale study. Results: Relapse rates differed significantly [ACTH 0.08, 95% confidence interval (CI) 0.01–0.54 versus IVMP 0.80, 95% CI 0.36–1.75; rate ratio, IVMP versus ACTH: 9.56, 95% CI 1.23–74.6; p = 0.03]. ACTH improved ( p = 0.03) MHI (slope 0.95 ± 0.38 points/month; p = 0.02 versus slope −0.38 ± 0.43 points/month; p = 0.39). On-study decreases (all p < 0.05) in eight cytokine levels occurred only in the ACTH group. However, on-study EDSS, MSFC, MS-QOL, BMD, and MRI lesion changes were not significant between groups. Psychiatric symptoms per patient were greater with IVMP than ACTH (0.55, 95% CI 0.12–2.6 versus 0; p < 0.0001). Other common adverse events were insomnia and urinary tract infections (IVMP, seven events each) and fatigue or flu symptoms (ACTH, five events each). Conclusions: This study provided class II evidence that ACTH produced better examiner-assessed cumulative rates of relapses per patient than IVMP in the adjunctive treatment of breakthrough disease in multiple sclerosis.
اللغة: English
تدمد: 1756-2864
1756-2856
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d1ffce1291cd858cf2fae618eca52d
https://doaj.org/article/669da6c82be84a56bc0897534748db53
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....29d1ffce1291cd858cf2fae618eca52d
قاعدة البيانات: OpenAIRE
ResultId 1
Header edsair
OpenAIRE
edsair.doi.dedup.....29d1ffce1291cd858cf2fae618eca52d
798
3

unknown
798.106689453125
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....29d1ffce1291cd858cf2fae618eca52d&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d1ffce1291cd858cf2fae618eca52d# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Adrenocorticotropic hormone methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Rohit+Bakshi%22&quot;&gt;Rohit Bakshi&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mohit+Neema%22&quot;&gt;Mohit Neema&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Shahamat+Tauhid%22&quot;&gt;Shahamat Tauhid&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Steven+Cen%22&quot;&gt;Steven Cen&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Robert+C%2E+Axtell%22&quot;&gt;Robert C. Axtell&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lilyana+Amezcua%22&quot;&gt;Lilyana Amezcua&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Regina+Berkovich%22&quot;&gt;Regina Berkovich&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lawrence+Steinman%22&quot;&gt;Lawrence Steinman&lt;/searchLink&gt; )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Therapeutic Advances in Neurological Disorders, Vol 10 (2017) )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => SAGE Publishing, 2017. )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2017 )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%220301+basic+medicine%22&quot;&gt;0301 basic medicine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%2Emedical%5Fspecialty%22&quot;&gt;medicine.medical_specialty&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Disease%22&quot;&gt;Disease&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Adrenocorticotropic+hormone%22&quot;&gt;Adrenocorticotropic hormone&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22lcsh%3ARC346-429%22&quot;&gt;lcsh:RC346-429&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Lesion%22&quot;&gt;Lesion&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%2203+medical+and+health+sciences%22&quot;&gt;03 medical and health sciences&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%220302+clinical+medicine%22&quot;&gt;0302 clinical medicine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Interferon+β%22&quot;&gt;Interferon β&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Internal+medicine%22&quot;&gt;Internal medicine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%22&quot;&gt;medicine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22lcsh%3ANeurology%2E+Diseases+of+the+nervous+system%22&quot;&gt;lcsh:Neurology. Diseases of the nervous system&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Pharmacology%22&quot;&gt;Pharmacology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Bone+mineral%22&quot;&gt;Bone mineral&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Expanded+Disability+Status+Scale%22&quot;&gt;Expanded Disability Status Scale&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22business%2Eindustry%22&quot;&gt;business.industry&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Multiple+sclerosis%22&quot;&gt;Multiple sclerosis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%2Edisease%22&quot;&gt;medicine.disease&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Surgery%22&quot;&gt;Surgery&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22030104+developmental+biology%22&quot;&gt;030104 developmental biology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Neurology%22&quot;&gt;Neurology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Methylprednisolone%22&quot;&gt;Methylprednisolone&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Neurology+%28clinical%29%22&quot;&gt;Neurology (clinical)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%2Esymptom%22&quot;&gt;medicine.symptom&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22business%22&quot;&gt;business&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22030217+neurology+%26+neurosurgery%22&quot;&gt;030217 neurology &amp; neurosurgery&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%2Edrug%22&quot;&gt;medicine.drug&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background: The objective of this study was to evaluate monthly intramuscular adrenocorticotropic hormone (ACTH) gel versus intravenous methylprednisolone (IVMP) add-on therapy to interferon β for breakthrough disease in patients with relapsing forms of multiple sclerosis. Methods: This was a prospective, open-label, examiner-blinded, 15-month pilot study evaluating patients with Expanded Disability Status Scale (EDSS) score 3.0–6.5 and at least one clinical relapse or new T2 or gadolinium-enhanced lesion in the previous year. Twenty-three patients were randomized to ACTH ( n = 12) or IVMP ( n = 11) and completed the study. The primary outcome measure was the cumulative number of relapses. Secondary outcomes included EDSS, Mental Health Inventory (MHI), plasma cytokines, MS Functional Composite (MSFC), Quality-of-Life (MS-QOL) score, bone mineral density (BMD), and new or worsened psychiatric symptoms per month. Brain magnetic resonance imaging was analyzed post hoc. This was a preliminary and small-scale study. Results: Relapse rates differed significantly [ACTH 0.08, 95% confidence interval (CI) 0.01–0.54 versus IVMP 0.80, 95% CI 0.36–1.75; rate ratio, IVMP versus ACTH: 9.56, 95% CI 1.23–74.6; p = 0.03]. ACTH improved ( p = 0.03) MHI (slope 0.95 &#177; 0.38 points/month; p = 0.02 versus slope −0.38 &#177; 0.43 points/month; p = 0.39). On-study decreases (all p &lt; 0.05) in eight cytokine levels occurred only in the ACTH group. However, on-study EDSS, MSFC, MS-QOL, BMD, and MRI lesion changes were not significant between groups. Psychiatric symptoms per patient were greater with IVMP than ACTH (0.55, 95% CI 0.12–2.6 versus 0; p &lt; 0.0001). Other common adverse events were insomnia and urinary tract infections (IVMP, seven events each) and fatigue or flu symptoms (ACTH, five events each). Conclusions: This study provided class II evidence that ACTH produced better examiner-assessed cumulative rates of relapses per patient than IVMP in the adjunctive treatment of breakthrough disease in multiple sclerosis. )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1756-2864&lt;br /&gt;1756-2856 )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => &lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d1ffce1291cd858cf2fae618eca52d&quot; linkWindow=&quot;_blank&quot;&gt;https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d1ffce1291cd858cf2fae618eca52d&lt;/link&gt;&lt;br /&gt;&lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://doaj.org/article/669da6c82be84a56bc0897534748db53&quot; linkWindow=&quot;_blank&quot;&gt;https://doaj.org/article/669da6c82be84a56bc0897534748db53&lt;/link&gt; )
Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....29d1ffce1291cd858cf2fae618eca52d )
RecordInfo Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => 0301 basic medicine [Type] => general ) [1] => Array ( [SubjectFull] => medicine.medical_specialty [Type] => general ) [2] => Array ( [SubjectFull] => Disease [Type] => general ) [3] => Array ( [SubjectFull] => Adrenocorticotropic hormone [Type] => general ) [4] => Array ( [SubjectFull] => lcsh:RC346-429 [Type] => general ) [5] => Array ( [SubjectFull] => Lesion [Type] => general ) [6] => Array ( [SubjectFull] => 03 medical and health sciences [Type] => general ) [7] => Array ( [SubjectFull] => 0302 clinical medicine [Type] => general ) [8] => Array ( [SubjectFull] => Interferon β [Type] => general ) [9] => Array ( [SubjectFull] => Internal medicine [Type] => general ) [10] => Array ( [SubjectFull] => medicine [Type] => general ) [11] => Array ( [SubjectFull] => lcsh:Neurology. Diseases of the nervous system [Type] => general ) [12] => Array ( [SubjectFull] => Pharmacology [Type] => general ) [13] => Array ( [SubjectFull] => Bone mineral [Type] => general ) [14] => Array ( [SubjectFull] => Expanded Disability Status Scale [Type] => general ) [15] => Array ( [SubjectFull] => business.industry [Type] => general ) [16] => Array ( [SubjectFull] => Multiple sclerosis [Type] => general ) [17] => Array ( [SubjectFull] => medicine.disease [Type] => general ) [18] => Array ( [SubjectFull] => Surgery [Type] => general ) [19] => Array ( [SubjectFull] => 030104 developmental biology [Type] => general ) [20] => Array ( [SubjectFull] => Neurology [Type] => general ) [21] => Array ( [SubjectFull] => Methylprednisolone [Type] => general ) [22] => Array ( [SubjectFull] => Neurology (clinical) [Type] => general ) [23] => Array ( [SubjectFull] => medicine.symptom [Type] => general ) [24] => Array ( [SubjectFull] => business [Type] => general ) [25] => Array ( [SubjectFull] => 030217 neurology & neurosurgery [Type] => general ) [26] => Array ( [SubjectFull] => medicine.drug [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Adrenocorticotropic hormone methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rohit Bakshi ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Mohit Neema ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shahamat Tauhid ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Steven Cen ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Robert C. Axtell ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Lilyana Amezcua ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Regina Berkovich ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Lawrence Steinman ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2017 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 17562864 ) [1] => Array ( [Type] => issn-print [Value] => 17562856 ) [2] => Array ( [Type] => issn-locals [Value] => edsair ) [3] => Array ( [Type] => issn-locals [Value] => edsairFT ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 10 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Therapeutic Advances in Neurological Disorders [Type] => main ) ) ) ) ) ) )
IllustrationInfo